Medtronic’s MiniMed 780G Gains CE Mark Expansion for Broader Use

Medtronic has received an expanded CE Mark for its MiniMed 780G automated insulin delivery system, now approved for children as young as two, pregnant individuals, and people with Type 2 diabetes in Europe. Previously used primarily for Type 1 diabetes, the system pairs an insulin pump with a glucose sensor to adjust insulin doses in real-time.

The label expansion is backed by clinical studies, including a pivotal trial involving 95 people with Type 2 diabetes, which showed a 0.7% drop in A1c and improved time-in-range glucose levels. Additional trials demonstrated safety and effectiveness in toddlers and during pregnancy.

Medtronic is also seeking FDA approval to extend the MiniMed 780G's use in the U.S. for similar populations. As the company prepares to spin off its diabetes unit, the 780G continues to drive growth—revenue from the segment rose 12% to $647 million, according to the company.

27-07-2025